{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:49:50Z","timestamp":1787312990480,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","immunology.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.iac.2014.04.008","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T22:30:26Z","timestamp":1405031426000},"page":"615-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Hypersensitivity Reactions to Biologic Agents"],"prefix":"10.1016","volume":"34","author":[{"given":"Alessandra","family":"Vultaggio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana C.","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2014.04.008_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-62703-586-6_3","article-title":"Therapeutic human monoclonal antibodies in inflammatory diseases","volume":"1060","author":"Kotsovilis","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.iac.2014.04.008_bib2","first-page":"178","article-title":"Monoclonal antibody-related drug for cancer therapy","volume":"7","author":"Li","year":"2013","journal-title":"Drug Discov Ther"},{"issue":"5","key":"10.1016\/j.iac.2014.04.008_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: history and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.iac.2014.04.008_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaut.2011.08.002","article-title":"Immune mediated adverse effects of biological used in the treatment of rheumatic diseases","volume":"37","author":"Borchers","year":"2011","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.iac.2014.04.008_bib5","unstructured":"Vultaggio A, Nencini F, Pratesi S, et\u00a0al. Manifestations of anti-drug antibodies response: hypersensitivity and infusion reactions. J Int Cyt Res, in press."},{"issue":"8","key":"10.1016\/j.iac.2014.04.008_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biologicals","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2014.04.008_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eci.10.90","article-title":"Acute infusion reactions induced by monoclonal antibody therapy","volume":"7","author":"Maggi","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.iac.2014.04.008_bib9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/cea.12098","article-title":"Allergological in\u00a0vitro and in\u00a0vivo evaluation of patients with hypersensitivity reactions to infliximab","volume":"43","author":"Matucci","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.iac.2014.04.008_bib10","first-page":"411","article-title":"Adverse drug reactions to biologics","volume":"8","author":"Scherer","year":"2010","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.iac.2014.04.008_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1537-2995.2004.03423.x","article-title":"Monoclonal antibody-stimulated serum sickness","volume":"44","author":"Proctor","year":"2004","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.iac.2014.04.008_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jemermed.2005.01.033","article-title":"Serum sickness-like reactions in patients receiving intravenous infliximab","volume":"30","author":"Gamarra","year":"2006","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.iac.2014.04.008_bib13","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C","article-title":"Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)","volume":"44","author":"D\u2019Arcy","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.iac.2014.04.008_bib14","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2007.06.038","article-title":"Severe serum sickness-like syndrome after omalizumab therapy for asthma","volume":"120","author":"Pilette","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2014.04.008_bib15","first-page":"656","article-title":"Allergic and nonallergic delayed infusion reactions during natalizumab therapy","volume":"65","author":"Hellwing","year":"2008","journal-title":"Arch Neurol"},{"issue":"24","key":"10.1016\/j.iac.2014.04.008_bib16","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1182\/blood-2011-08-371138","article-title":"A\u00a0distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis","volume":"118","author":"Cuker","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.iac.2014.04.008_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMc1005108","article-title":"Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"363","author":"Berzuini","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2014.04.008_bib18","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.2174\/138161208786369786","article-title":"Hypersensitivity reactons to last generation chimeric, humanized and human recombinant monoclonal antibodies for therapeutic use","volume":"14","author":"Calogiuri","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.iac.2014.04.008_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2310\/6620.2009.09010a","article-title":"A\u00a0mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease. Part 1","volume":"20","author":"Bremmer","year":"2009","journal-title":"Dermatitis"},{"key":"10.1016\/j.iac.2014.04.008_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/archderm.138.9.1258","article-title":"Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern","volume":"138","author":"Vergara","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2014.04.008_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2310\/6620.2009.09010b","article-title":"A\u00a0mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease. Part 2","volume":"20","author":"Bremmer","year":"2009","journal-title":"Dermatitis"},{"key":"10.1016\/j.iac.2014.04.008_bib22","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1200\/JCO.2007.15.7883","article-title":"Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.iac.2014.04.008_bib23","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reactrion","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.iac.2014.04.008_bib24","first-page":"5","article-title":"Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events","volume":"20","author":"Lenz","year":"2006","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.iac.2014.04.008_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1517\/14740338.2013.755957","article-title":"Selective TNF-a inhibitor induced-injection site reactions","volume":"12","author":"Murdaca","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.iac.2014.04.008_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/ACI.0b013e3283464bcd","article-title":"Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management","volume":"11","author":"Vultaggio","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15476910801897433","article-title":"Monoclonal antibody first dose cytokine release syndrome - mechanisms and prediction","volume":"5","author":"Wing","year":"2008","journal-title":"J\u00a0Immunotoxicology"},{"issue":"3","key":"10.1016\/j.iac.2014.04.008_bib28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan","year":"2010","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.iac.2014.04.008_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2014.04.008_bib30","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-\u03b1 biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.iac.2014.04.008_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaci.2007.07.033","article-title":"Anaphylaxis: lessons from mouse model","volume":"120","author":"Finkelman","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib32","first-page":"343","article-title":"Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection","volume":"66","author":"Georgitis","year":"1991","journal-title":"Ann Allergy"},{"key":"10.1016\/j.iac.2014.04.008_bib33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.clinthera.2010.07.021","volume":"32","author":"Stubenrauch","year":"2010","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.iac.2014.04.008_bib34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1398-9995.2011.02601.x","article-title":"Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization","volume":"66","author":"Bavbek","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2014.04.008_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2010.05.004","article-title":"Biological agents: new drugs, old problems","volume":"126","author":"Munoz-Cano","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2014.04.008_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000336839","article-title":"Drug-specific th2 cells and ige antibodies in a patient with anaphylaxis to rituximab","volume":"359","author":"Vultaggio","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib38","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs:105 desensitizations in 23 patients, from evalutaion to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/039463200802100214","article-title":"Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience","volume":"21","author":"Vultaggio","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.iac.2014.04.008_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2011.04699.x","article-title":"A\u00a0one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study","volume":"34","author":"Lee","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.iac.2014.04.008_bib41","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2014.04.008_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2500\/aap.2007.28.3003","article-title":"Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy","volume":"28","author":"Price","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.iac.2014.04.008_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1440-1797.2005.00389.x","article-title":"Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin","volume":"10","author":"Steele","year":"2005","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"10.1016\/j.iac.2014.04.008_bib44","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2011.06.050","article-title":"T-cell involvement in delayed type hypersensitivity reactions to infliximab","volume":"128","author":"Torres","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1034\/j.1398-9995.2002.1n3435.x","article-title":"T\u00a0cell mediated allergy to abciximab","volume":"57","author":"Moneret-Vautrin","year":"2002","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2014.04.008_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archderm.142.2.218","article-title":"Eosinophilic cellulitis like reaction to subcutaneous etanercept injection","volume":"142","author":"Winfield","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2014.04.008_bib47","first-page":"953","article-title":"Etanercept-induced injection site reactions, mechanistic insights from clinical fidings and immunohistochemistry","volume":"137","author":"Werth","year":"2001","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2014.04.008_bib48","first-page":"333","article-title":"Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis","volume":"27","author":"Benucci","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"15","key":"10.1016\/j.iac.2014.04.008_bib49","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","article-title":"Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis","volume":"173","author":"Maneiro","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.iac.2014.04.008_bib50","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2010.02.025","article-title":"Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune disease","volume":"125","author":"Lee","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib51","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2006-11-059469","article-title":"Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safetly be delivered in the community setting","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.iac.2014.04.008_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","article-title":"Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles","volume":"34","author":"Anderson","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.iac.2014.04.008_bib53","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.iac.2014.04.008_bib54","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.iac.2014.04.008_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2133.2008.08728.x","article-title":"Review and expert opinion on prevention and treatment of infliximab-related infusion reactions","volume":"159","author":"Lecluse","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2014.04.008_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.2012.630388","article-title":"Update upon efficacy and safety of TNF-a inhibitors","volume":"11","author":"Murdaca","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.iac.2014.04.008_bib57","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","article-title":"Infusion reactions: diagnosis, assessment and management","volume":"14","author":"Vogel","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.iac.2014.04.008_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Reccomendations for the design and optimization of immunoassay used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J\u00a0Immunol Methods"},{"issue":"1\u20132","key":"10.1016\/j.iac.2014.04.008_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jim.2011.09.011","article-title":"Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing","volume":"375","author":"Rispens","year":"2012","journal-title":"J\u00a0Immunol Methods"},{"issue":"4","key":"10.1016\/j.iac.2014.04.008_bib60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","article-title":"Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement","volume":"20","author":"Aarden","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1352458507079945","article-title":"Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis","volume":"14","author":"Serarslan","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.iac.2014.04.008_bib62","first-page":"s317","article-title":"Evaluation d\u2019une pratique de prise en charge des taxidermies dues a l\u2019interferon: a propos de 15 cas","volume":"136","author":"Poreaux","year":"2009","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.iac.2014.04.008_bib63","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.04.008_bib64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00054725-200102000-00005","article-title":"Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction","volume":"7","author":"Puchner","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.iac.2014.04.008_bib65","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.iac.2014.04.008_bib66","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2006.03026.x","article-title":"Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions","volume":"24","author":"Duburque","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.iac.2014.04.008_bib67","first-page":"246","article-title":"Successful adalimumab desensitization after generalized urticaria and rhinitis","volume":"19","author":"Rodriguez-Jimenez","year":"2009","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2014.04.008_bib68","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.aller.2012.04.006","article-title":"Injection site reaction to adalimumab: positive skin test and successful rapid desensitization","volume":"41","author":"Bavbek","year":"2013","journal-title":"Allergol Immunopathol"},{"issue":"1","key":"10.1016\/j.iac.2014.04.008_bib69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-009-1009-6","article-title":"Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer","volume":"65","author":"Saif","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.iac.2014.04.008_bib70","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2008.09.046","article-title":"A\u00a0desensitization protocol for the mAb cetuximab","volume":"123","author":"Jerath","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.iac.2014.04.008_bib71","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1159\/000055403","article-title":"Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer","volume":"61","author":"Cook-Bruns","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.iac.2014.04.008_bib72","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mai.2002.128689","article-title":"Rapid desensitization and rush immunotherapy to trastuzumab","volume":"110","author":"Melamad","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.04.008_bib73","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jaci.2009.06.014","article-title":"Mammalian meat-induced anhaphylaxis: clinical relevance of anti-galactose-a-1,3-galactose IgE confirmed by means of skin tests to cetuximab","volume":"124","author":"Jacquener","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T17:56:43Z","timestamp":1717005403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856114000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0889856114000435"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2014.04.008","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypersensitivity Reactions to Biologic Agents","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2014.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}